Page 150 - ADULT-ONSET ASTHMA PREDICTORS OF CLINICAL COURSE AND SEVERITY
P. 150
ADULT-ONSET ASTHMA – PREDICTORS OF CLINICAL COURSE AND SEVERITY
Table 2. Comparison of (ex)smokers with and without frequent exacerbations. Non-exacerbator (n=45) Exacerbator (n=38)
p-value
0.518 0.618 0.225 0.040 0.404 0.251 0.932 0.123 0.009 0.001 0.098 0.517 0.841 0.518 0.540
0.067 0.365 0.976 0.871 0.680
Age, years
Sex, % female
Age of asthma onset
Asthma duration, years
BMI, kg/m2
Positive family history of asthma,%
Current smoker, %
Pack years
ICS dose *
Chronic OCS use, %
Atopy, %
Chronic rhinosinusitis, %
GERD, %
ACQ-6 score
AQLQ 5.0
Pb FEV1, % predicted
Pb FEV1/FVC, % predicted RV/TLC ratio, % predicted TLCOc/VA, % predicted PC20 (methacholine), mg/ml
FeNO, ppb
Blood neutrophils, 109 cells/L
Blood eosinophils, 109 cells/L
Total IgE, kU/L
Sputum neutrophil %
Sputum eosinophil %
91 (19) 83 88 (14) 85 98 (20) 99
101 (18) 102 3.2 (3.8) 3.9
19 (13-38) 35 4.1 (3.2-5.1) 5.0 0.19 (0.13-0.44) 0.18 63 (22-242) 111 53 (34-71) 63 1.0 (0-37.1) 5.2
(12-93)
(3.8-6.4)
(0.08-0.34)
(32-291)
(39-76)
(0.4-23.6)
fluticasone equivalent. Pb:
53 (10) 54 58 63 45 (13) 41
4 (0-10) 7 28.6 (5.0) 29.5 41 56 11 11 10 (5-24) 8 500 (500-1000) 1000 13 45 38 21 18 24 38 36 1.9 (0.8) 2.1 (1.1) 4.8
(11)
(14) (2-21) (5.4)
(4-16) (500-1500)
(1.1) (1.0)
(19) (15) (21) (15) (6.4)
0.131
0.008
0.371 0.370 0.221 0.469
Data presented as percentage, mean (SD) or median
postbronchodilator. ppb: parts per billion.
(interquartile range). * ICS dose in
2
148
